80 related articles for article (PubMed ID: 3071765)
1. High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: preliminary data of a phase-II study.
Nagel GA; Rauschning W; Ammon A; Beyer JH; Emrich D; Holtkamp W; Kneba M; Luig H; Marschner N; Unger C
Onkologie; 1988 Dec; 11(6):289-91. PubMed ID: 3071765
[No Abstract] [Full Text] [Related]
2. High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.
Nagel GA; Beyer JH; Holtkamp W; Emrich D; Kneba M; Luig H; Marschner N; Rauschning W; Unger C; Wander HE
Onkologie; 1988 Dec; 11(6):287-8. PubMed ID: 3071764
[No Abstract] [Full Text] [Related]
3. High-dose epirubicin in combination with cyclophosphamide (HD-EC) in advanced breast cancer: final results of a dose finding study and phase II trial.
Marschner N; Nagel GA; Beyer JH; Adler M; Ammon A
Onkologie; 1990 Aug; 13(4):272-8. PubMed ID: 2234780
[TBL] [Abstract][Full Text] [Related]
4. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
[TBL] [Abstract][Full Text] [Related]
5. [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
Shinagawa K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3277-81. PubMed ID: 3143311
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Langley RE; Carmichael J; Jones AL; Cameron DA; Qian W; Uscinska B; Howell A; Parmar M
J Clin Oncol; 2005 Nov; 23(33):8322-30. PubMed ID: 16293863
[TBL] [Abstract][Full Text] [Related]
7. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM
J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507
[TBL] [Abstract][Full Text] [Related]
9. UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
Gregory RK; Johnston SR; Smith IE; Miles D
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):47-9. PubMed ID: 11098493
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results.
Zaniboni A; Marpicati P; Simoncini E; Gorni F; Ferrari V; Raffaglio E; Garattini MP; Marini G
Anticancer Res; 1987; 7(4B):813-5. PubMed ID: 3479042
[TBL] [Abstract][Full Text] [Related]
11. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
Untch M; Eidtmann H; du Bois A; Meerpohl HG; Thomssen Ch; Ebert A; Harbeck N; Jackisch C; Heilman V; Emons G; Wallwiener D; Wiese W; Blohmer JU; Höffken K; Kuhn W; Reichardt P; Muscholl M; Pauschinger M; Langer B; Lück HJ
Eur J Cancer; 2004 May; 40(7):988-97. PubMed ID: 15093573
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.
Marschner N; Kreienberg R; Souchon R; Räth U; Eggeling B; Voigtmann R; Ruffert K; Schütte M; Ammon A; Kesztyüs T
Semin Oncol; 1994 Feb; 21(1 Suppl 1):10-6. PubMed ID: 8153652
[No Abstract] [Full Text] [Related]
13. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
14. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
[TBL] [Abstract][Full Text] [Related]
16. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Bonneterre J; Tubiana-Hulin M; Catimel G
Oncology; 2004; 66(3):185-91. PubMed ID: 15218308
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of advanced cancer of the breast with FEC polychemotherapy using epirubicin at 75 mg/m2 dose (FEC 75)].
Perez Carrion R; Jimeno JM; Jimenez V; Guardiola L; Donnay O; Sanchez J
Bull Cancer; 1990; 77(10):1033-5. PubMed ID: 2249014
[No Abstract] [Full Text] [Related]
19. Phase II study of combination vincristine, epirubicin and cyclophosphamide in advanced breast cancer in Chinese patients.
Shiu W; Tao M; Leung T
Eur J Cancer; 1991; 27(12):1710. PubMed ID: 1782089
[No Abstract] [Full Text] [Related]
20. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
